MX365773B - Inhibidores de fosfodiesterasas por via transvaginal para el tratamiento de la infertabilidad. - Google Patents

Inhibidores de fosfodiesterasas por via transvaginal para el tratamiento de la infertabilidad.

Info

Publication number
MX365773B
MX365773B MX2013015280A MX2013015280A MX365773B MX 365773 B MX365773 B MX 365773B MX 2013015280 A MX2013015280 A MX 2013015280A MX 2013015280 A MX2013015280 A MX 2013015280A MX 365773 B MX365773 B MX 365773B
Authority
MX
Mexico
Prior art keywords
phosphodiesterase inhibitors
infertility
treatment
applied via
inhibitors applied
Prior art date
Application number
MX2013015280A
Other languages
English (en)
Other versions
MX2013015280A (es
Inventor
Carmen Pardina Palleja Maria
Angel Vaz-Romero Uña Miguel
Original Assignee
Prokrea Bcn S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prokrea Bcn S L filed Critical Prokrea Bcn S L
Publication of MX2013015280A publication Critical patent/MX2013015280A/es
Publication of MX365773B publication Critical patent/MX365773B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una nueva aplicación de los inhibidores de fosfodiesterasas para el tratamiento de la infertilidad de parejas, que constituye una alternativa eficaz a las técnicas invasivas de reproducción asistida, como la inseminación artificial conyugal, y que consiste en la administración transvaginal de un inhibidor de fosfodiesterasas inmediatamente antes y/o después de realizar el coito. También se refiere a formas farmacéuticas aptas para la administración intravaginal de inhibidores de fosfodiesterasas.
MX2013015280A 2011-06-23 2012-06-20 Inhibidores de fosfodiesterasas por via transvaginal para el tratamiento de la infertabilidad. MX365773B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201131059A ES2395801B1 (es) 2011-06-23 2011-06-23 "pentoxifilina por vía transvaginal para el tratamiento de la infertilidad"
PCT/ES2012/070453 WO2012175775A1 (es) 2011-06-23 2012-06-20 Inhibidores de fosfodiesterasas por vía transvaginal para el tratamiento de la infertilidad

Publications (2)

Publication Number Publication Date
MX2013015280A MX2013015280A (es) 2014-08-01
MX365773B true MX365773B (es) 2019-06-10

Family

ID=46603994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013015280A MX365773B (es) 2011-06-23 2012-06-20 Inhibidores de fosfodiesterasas por via transvaginal para el tratamiento de la infertabilidad.

Country Status (21)

Country Link
US (2) US9220679B2 (es)
EP (1) EP2724716B1 (es)
JP (2) JP6373755B2 (es)
KR (1) KR101948355B1 (es)
AU (1) AU2012273879B2 (es)
BR (1) BR112013032855A2 (es)
CA (1) CA2846498C (es)
CY (1) CY1119860T1 (es)
DK (1) DK2724716T3 (es)
ES (2) ES2395801B1 (es)
HR (1) HRP20180105T1 (es)
HU (1) HUE036489T2 (es)
LT (1) LT2724716T (es)
MX (1) MX365773B (es)
NO (1) NO2724716T3 (es)
PL (1) PL2724716T3 (es)
PT (1) PT2724716T (es)
RS (1) RS56921B1 (es)
RU (1) RU2601913C2 (es)
SI (1) SI2724716T1 (es)
WO (1) WO2012175775A1 (es)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US3422107A (en) 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
JPS5229318B2 (es) 1972-03-30 1977-08-01
DE2413935A1 (de) 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
JPS52156913A (en) * 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
ZA807267B (en) 1979-11-26 1981-11-25 Sterling Drug Inc 5-(pyridinyl)-2(1h)-pyridinones,useful as cardiotonic agents and their preparation
GB8607570D0 (en) * 1986-03-26 1986-04-30 Euro Celtique Sa Vaginal pharmaceutical preparation
JPH0347134A (ja) * 1989-03-08 1991-02-28 Hoechst Japan Ltd ヒドロゲル製剤およびキセロゲル製剤の製造法
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
US20040014761A1 (en) 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
WO1999021562A1 (en) * 1997-10-28 1999-05-06 Asivi, Llc Treatment of female sexual dysfunction
DE19801438A1 (de) * 1998-01-16 1999-07-29 Haemopep Pharma Gmbh Verwendung von spezifischen Phosphodiesterase-Inhibitoren zur Erhöhung der Spermienmotilität
WO1999062533A1 (en) 1998-06-04 1999-12-09 Jedco Products, Llc Preparation for topical application to the male sexual organ
US20050075284A1 (en) * 2000-05-22 2005-04-07 Illana Gozes Pharmaceutical compositions comprising vip-related peptides for the treatment of sexual disorders
AU2001241730B2 (en) * 2001-02-23 2007-03-15 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
EP1404336A1 (en) * 2001-06-14 2004-04-07 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
JP4651944B2 (ja) * 2002-02-07 2011-03-16 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 殺精子剤および殺菌剤からの粘膜刺激の予防のための亜鉛塩組成物
EP1473034A1 (en) * 2003-03-17 2004-11-03 Lagow GmbH Use of an inhibitor of the phosphodiesterase-4-enzyme (PDE4) alone or in combination with relaxin and derivatives thereof for the manufacture of a medicament to promote decidualization of endometrial cells and to increase fertility
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
JP2007522077A (ja) * 2003-08-21 2007-08-09 アクセス ファーマシューティカルズ， インコーポレイテッド 粘膜の疾患および障害の予防および処置のための液体製剤
ES2245609B1 (es) 2004-06-18 2007-08-16 Universidad De Barcelona Nuevo agente terapeutico para el tratamiento de la infertilidad y/o subfertilidad masculina en mamiferos.
TW201444869A (zh) * 2005-06-30 2014-12-01 Abbvie Inc Ｉｌ-１２／ｐ４０結合蛋白
CN102438645A (zh) * 2009-01-13 2012-05-02 卢布里斯有限责任公司 阴道上皮界面润滑的治疗调节

Also Published As

Publication number Publication date
US20140194448A1 (en) 2014-07-10
CA2846498C (en) 2019-01-15
LT2724716T (lt) 2018-02-26
PT2724716T (pt) 2017-12-26
SI2724716T1 (en) 2018-03-30
ES2395801A1 (es) 2013-02-15
HRP20180105T1 (hr) 2018-03-23
US9220679B2 (en) 2015-12-29
HUE036489T2 (hu) 2018-07-30
MX2013015280A (es) 2014-08-01
EP2724716B1 (en) 2017-11-22
RS56921B1 (sr) 2018-05-31
JP6373755B2 (ja) 2018-08-15
RU2014101761A (ru) 2015-08-20
JP2014518221A (ja) 2014-07-28
NO2724716T3 (es) 2018-04-21
ES2395801B1 (es) 2014-06-06
RU2601913C2 (ru) 2016-11-10
CA2846498A1 (en) 2012-12-27
DK2724716T3 (en) 2018-02-12
KR20140043927A (ko) 2014-04-11
KR101948355B1 (ko) 2019-02-14
JP2017075185A (ja) 2017-04-20
AU2012273879B2 (en) 2017-04-13
PL2724716T3 (pl) 2018-04-30
JP6347858B2 (ja) 2018-06-27
EP2724716A1 (en) 2014-04-30
CY1119860T1 (el) 2018-06-27
AU2012273879A1 (en) 2014-02-06
BR112013032855A2 (pt) 2017-01-24
ES2656204T3 (es) 2018-02-26
US20160074407A1 (en) 2016-03-17
WO2012175775A1 (es) 2012-12-27

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
MX2018015892A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
UA115983C2 (uk) Інгібітори днк-пк
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
CL2012003110A1 (es) Compuestos derivados de n-[(2-oxo-1,2-dihidro-3-piridinil)metil]-1h-indol-4-carboxamida, inhibidores de ezh2; composicion farmaceutica que los contiene; utiles en el tratamiento del cancer seleccionado del grupo que consiste de cerebro (gliomas) glioblastomas, leucemias y linfomas, y trastornos mediados por la inhibicion del ezh2.
EA201500362A1 (ru) Ингибиторы rho-киназы
PH12015500719A1 (en) Gdf-8-inhibitors
MX2015010921A (es) Compuestos de carbazol utiles como inhibidores de bromodominio.
MX2016004604A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores.
MX362550B (es) Inhibidores ciclicos de glutaminasa.
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
IN2014DN10548A (es)
MY162397A (en) Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
EA201201201A1 (ru) Новые ингибиторы rock
MX348726B (es) Inhibición del il17 e ifn-gamma para el tratamiento de inflamación autoinmune.
PH12016502353A1 (en) Pharmaceutical composition
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
MX2019003317A (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).
PH12018500096A1 (en) Mdm2 inhibitors for treating uveal melanoma
GB201312965D0 (en) Stem cell factor inhibitor
MA32933B1 (fr) Combinaison d'inhibiteurs de hspo90 et d'herceptine
MX2013015280A (es) Inhibidores de fosfodiesterasas por via transvaginal para el tratamiento de la infertabilidad.

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: PROKREA BCN, S.L.

FG Grant or registration